|
|
UNITED STATES |
OMB APPROVAL |
|
|
SECURITIES AND EXCHANGE COMMISSION |
OMB Number: |
|
|
Washington, D.C. 20549 |
Expires: |
|
|
SCHEDULE 13G |
Estimated average burden hours per response. . 11 |
Under the Securities Exchange Act of 1934
(Amendment No. 25)*
Abbott Laboratories
(Name of Issuer)
Common Stock without par value
(Title of Class of Securities)
002824 10 0
(CUSIP Number)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
ý |
Rule 13d-1(b) |
|
o |
Rule 13d-1(c) |
|
o |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 002824 10 0 |
|||||
|
|
|||||
|
|
1. |
Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only) I.R.S. Identification No. 36-6047554 |
|||
|
|
|||||
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|||
|
|
|
(a) |
o |
||
|
|
|
(b) |
ý |
||
|
|
|||||
|
|
3. |
SEC Use Only |
|||
|
|
|||||
|
|
4. |
Citizenship or Place of Organization |
|||
|
|
|
|
|||
|
Number of |
5. |
Sole Voting Power |
|||
|
|
|||||
|
6. |
Shared Voting Power |
||||
|
|
|||||
|
7. |
Sole Dispositive Power |
||||
|
|
|||||
|
8. |
Shared
Dispositive Power |
||||
|
|
|||||
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|||
|
|
|||||
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) o |
|||
|
|
|||||
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|||
|
|
|||||
|
|
12. |
Type of Reporting Person (See Instructions) |
|||
2
|
|
1. |
Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only) |
||||
|
|
||||||
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
||||
|
|
|
(a) |
o |
|||
|
|
|
(b) |
ý |
|||
|
|
||||||
|
|
3. |
SEC Use Only |
||||
|
|
||||||
|
|
4. |
Citizenship or Place of Organization |
||||
|
|
|
|
||||
|
Number of |
5. |
Sole Voting Power |
(Does not
include shares held in the Abbott |
|||
|
|
||||||
|
6. |
Shared Voting Power |
|||||
|
|
||||||
|
7. |
Sole Dispositive Power 155,614 shares (see note in 5 above) |
|||||
|
|
||||||
|
8. |
Shared
Dispositive Power |
|||||
|
|
||||||
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
||||
|
|
||||||
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) o |
||||
|
|
||||||
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
||||
|
|
||||||
|
|
12. |
Type of Reporting Person (See Instructions) |
||||
3
|
|
1. |
Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only) |
||||
|
|
||||||
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
||||
|
|
|
(a) |
o |
|||
|
|
|
(b) |
ý |
|||
|
|
||||||
|
|
3. |
SEC Use Only |
||||
|
|
||||||
|
|
4. |
Citizenship or Place of Organization |
||||
|
|
|
|
||||
|
Number of |
5. |
Sole Voting Power |
(Does not
include shares held in the Abbott |
|||
|
|
||||||
|
6. |
Shared Voting Power |
|||||
|
|
||||||
|
7. |
Sole Dispositive Power |
|||||
|
|
||||||
|
8. |
Shared
Dispositive Power |
|||||
|
|
||||||
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
||||
|
|
||||||
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) o |
||||
|
|
||||||
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
||||
|
|
||||||
|
|
12. |
Type of Reporting Person (See Instructions) |
||||
4
|
|
1. |
Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only) |
||||
|
|
||||||
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
||||
|
|
|
(a) |
o |
|||
|
|
|
(b) |
ý |
|||
|
|
||||||
|
|
3. |
SEC Use Only |
||||
|
|
||||||
|
|
4. |
Citizenship or Place of Organization |
||||
|
|
|
|
||||
|
Number of |
5. |
Sole Voting Power |
(Does not
include shares held in the Abbot |
|||
|
|
||||||
|
6. |
Shared Voting Power |
|||||
|
|
||||||
|
7. |
Sole Dispositive Power 60,498
shares (see note in 5 above) |
|||||
|
|
||||||
|
8. |
Shared
Dispositive Power |
|||||
|
|
||||||
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
||||
|
|
||||||
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) o |
||||
|
|
||||||
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
||||
|
|
||||||
|
|
12. |
Type of Reporting Person (See Instructions) |
||||
5
|
Item 1. |
||
|
|
(a) |
Name
of Issuer |
|
|
(b) |
Address
of Issuer’s Principal Executive Offices |
|
|
||
|
Item 2. |
||
|
|
(a) |
Name
of Person Filing Thomas C. Freyman Terrence C. Kearney Thomas M. Wascoe |
|
|
(b) |
Address
of Principal Business Office or, if none, Residence Abbott Park, Illinois 60064-6400 |
|
|
(c) |
Citizenship Thomas C. Freyman, Terrence C. Kearney, and Thomas M. Wascoe - United States
|
|
|
(d) |
Title
of Class of Securities |
|
|
(e) |
CUSIP
Number |
6
|
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
||||
|
|
(a) |
o |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
||
|
|
(b) |
o |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
||
|
|
(c) |
o |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
||
|
|
(d) |
o |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
||
|
|
(e) |
o |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
||
|
|
(f) |
ý |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
||
|
|
(g) |
o |
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
||
|
|
(h) |
o |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
||
|
|
(i) |
o |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
||
|
|
(j) |
o |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
||
|
|
|
|
|
||
|
Item 4. |
Ownership |
||||
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
|||||
|
|
(a) |
(See cover pages 2, 3, |
|||
|
|
(b) |
4 and 5, Items 5 through |
|||
|
|
(c) |
9 and 11.) |
|||
|
|
|||||
|
Item 5. |
Ownership of Five Percent or Less of a Class |
||||
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o. |
|||||
|
|
Not applicable. |
||||
|
|
|||||
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person |
||||
|
|
The shares owned by the Abbott Laboratories Stock Retirement Trust and the dividends thereon are held for the benefit of participants of the Abbott Laboratories Stock Retirement Plan pursuant to the terms of that Plan and the Trust. The Abbott Laboratories Stock Retirement Plan is a qualified employee stock ownership plan. As of December 31, 2003, there were 43,695 participants with share balances in the Plan. |
||||
|
|
|||||
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
||||
|
|
Not applicable. |
||||
|
|
|||||
|
Item 8. |
Identification and Classification of Members of the Group |
||||
|
|
Not applicable. |
||||
|
|
|||||
|
Item 9. |
Notice of Dissolution of Group |
||||
|
|
Not applicable. |
||||
|
|
|||||
|
Item 10. |
Certification |
||||
|
|
Not applicable. |
||||
7
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. This statement is filed on behalf of each individual listed below pursuant to their agreement.
|
Date: February 12, 2004 |
ABBOTT LABORATORIES STOCK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Thomas C. Freyman |
|
|
|
|
Thomas C. Freyman, Co-Trustee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Terrence C. Kearney |
|
|
|
|
Terrence C. Kearney, Co-Trustee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Thomas M. Wascoe |
|
|
|
|
Thomas M. Wascoe, Co-Trustee |
||
8
EXHIBIT 1
Schedule 13G
Amendment No. 25
Abbott Laboratories
Common shares without par value
CUSIP Number 002824 10 0
Messrs. Freyman, Kearney, and Wascoe are Co-trustees of the Abbott Laboratories Stock Retirement Trust, committee members of a committee established under the Abbott Laboratories Stock Retirement Trust (Puerto Rico), Trustees of the Abbott Laboratories Employee Benefit Trust, and members of the Abbott Stock Committee for the Abbott Laboratories Ashland Union 401(k) Trust. As such, each of them has shared voting power over the 87,405,438 shares held by those trusts. This total is comprised of the following components:
|
Number of Shares |
|
Name of Trust |
|
84,081,627 |
|
Abbott Laboratories Stock Retirement Trust |
|
|
|
|
|
3,198,464 |
|
Abbott Laboratories Stock Retirement Trust (Puerto Rico) |
|
|
|
|
|
52,000 |
|
Abbott Laboratories Employee Benefit Trust |
|
|
|
|
|
73,347 |
|
Abbott Laboratories Ashland Union 401(k) Trust |
1
Disclaimer of Beneficial Ownership
under Rule 13d-4
The filing of Schedule 13G Amendment 25 on behalf of the Abbott Laboratories Stock Retirement Trust does not constitute an admission that the undersigned is, for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the beneficial owner of any securities covered by the Schedule. Pursuant to Rule 13d-4 of the Act, the undersigned disclaims such ownership with respect to any shares listed therein of which he would not otherwise be deemed to be beneficial owner.
|
|
/s/ Thomas C. Freyman |
|
|
|
Thomas C. Freyman |
|
|
|
|
|
|
|
|
|
|
|
Date: February 12 , 2004 |
|
2
Disclaimer of Beneficial Ownership
under Rule 13d-4
The filing of Schedule 13G Amendment 25 on behalf of the Abbott Laboratories Stock Retirement Trust does not constitute an admission that the undersigned is, for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the beneficial owner of any securities covered by the Schedule. Pursuant to Rule 13d-4 of the Act, the undersigned disclaims such ownership with respect to any shares listed therein of which he would not otherwise be deemed to be beneficial owner.
|
|
/s/ Terrence C. Kearney |
|
|
|
Terrence C. Kearney |
|
|
|
|
|
|
|
|
|
|
|
Date: February 12, 2004 |
|
3
Disclaimer of Beneficial Ownership
under Rule 13d-4
The filing of Schedule 13G Amendment 25 on behalf of the Abbott Laboratories Stock Retirement Trust does not constitute an admission that the undersigned is, for purposes of Section 13(d) of the Securities and Exchange Act of 1934, the beneficial owner of any securities covered by the Schedule. Pursuant to Rule 13d-4 of the Act, the undersigned disclaims such ownership with respect to any shares listed therein of which she would not otherwise be deemed to be beneficial owner.
|
|
/s/ Thomas M. Wascoe |
|
|
|
Thomas M. Wascoe |
|
|
|
|
|
|
|
|
|
|
|
Date: February 12 , 2004 |
|
4